Neurologix to Present at Collins Stewart Fourth Annual Growth Conference

FORT LEE, N.J.--(BUSINESS WIRE)--Neurologix, Inc. (OTCBB: NRGX), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today that it is scheduled to present at the Collins Steward Fourth Annual Growth Conference on Thursday, July 10, 2008. John Mordock, Neurologix President and Chief Executive Officer, will discuss the company’s business strategy and corporate overview from 10:00 – 10:30 am (ET) at the Mandarin Oriental Hotel in New York City.

The presentation will be webcast live and can be accessed on the Neurologix website, http://www.neurologix.net, in the investor relations section. A replay will be available approximately 24 hours after the presentation and will be archived on the company’s website for two weeks.

About Neurologix

Neurologix, Inc. (NRGX.OB) is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of life-altering gene transfer therapies for serious disorders of the brain and Central Nervous System (CNS). Neurologix’s therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses. Current company programs address such conditions as Parkinson’s disease, epilepsy and Huntington’s chorea, all of which are large markets not adequately served by current therapeutic options. For more information, please visit the Neurologix website at http://www.neurologix.net.